FDA Orange Book · active-ingredient family
Balsalazide disodium
Balsalazide disodium: 2 brands, 6 generics; first approved Jul 18, 2000; generic available.
Generic availableHas discontinued products
Generic status & protection
Generic available: 6 ANDA applications approved.
Earliest patent expiry
Brands (NDA)
2
Generics (ANDA)
6
Listed patents
6
Next patent expiry
Aug 02, 2026
3 mo ago
Brand (NDA) products
Originator applications
Generic (ANDA) products (6)
Abbreviated applications
- BALSALAZIDE DISODIUMCARNEGIEANDA 2194222025
Approved strengths under this FDA application. Strength Dosage form Route Status TE 750MG CAPSULE ORAL Rx AB - BALSALAZIDE DISODIUMZYDUS LIFESCIENCESANDA 2175922023
Approved strengths under this FDA application. Strength Dosage form Route Status TE 750MG CAPSULE ORAL Rx AB - BALSALAZIDE DISODIUMAARXION ANDA HLDINGANDA 2063362015
Approved strengths under this FDA application. Strength Dosage form Route Status TE 1.1GM TABLET ORAL Discontinued - - BALSALAZIDE DISODIUMAPOTEXANDA 0778832007
Approved strengths under this FDA application. Strength Dosage form Route Status TE 750MG CAPSULE ORAL Rx AB - BALSALAZIDE DISODIUMHIKMAANDA 0778062007
Approved strengths under this FDA application. Strength Dosage form Route Status TE 750MG CAPSULE ORAL Rx AB - BALSALAZIDE DISODIUMNOVITIUM PHARMAANDA 0778072007
Approved strengths under this FDA application. Strength Dosage form Route Status TE 750MG CAPSULE ORAL Rx AB
Patent & exclusivity timeline
Protection horizon
Patent expiryExclusivity endToday
Listed patents
Orange Book patent file
| Patent | Expires | In | Type |
|---|---|---|---|
| 9192616 | 3 mo ago | U-1229 | |
| 7625884 | 2 mo ago | U-141 | |
| 7452872 | 2 mo ago | U-141 | |
| 7452872*PED | in 4 mo | ||
| 7625884*PED | in 4 mo | ||
| 8497256 | in 4 yr 9 mo | U-1229 |
Approval history
FDA approval span
First approval
26 yr 8 mo ago
Most recent approval
1 yr 7 mo ago
Approvals span 2000–2025 across 8 FDA applications.
Brand (NDA) 225%
Generic (ANDA) 675%
Balsalazide disodium: frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.
Built directly from the FDA Orange Book data file (products, patents, and exclusivity). TE codes, RLD/RS flags, patent expirations, and exclusivity dates match the official FDA record. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
Related FDA reference tools
- FDA Purple BookLicensed biologics, biosimilars, interchangeables, BLA records, and exclusivity dates.
- FDA BiosimilarsFDA-approved biosimilars and interchangeable biosimilars, by reference product.
- 510(k) Predicate DatabaseSearch FDA 510(k) clearances and map predicate-device lineage.
- FDA 483 DatabaseFDA Form 483 observations and inspection records by firm, date, and citation.
Assyro Intelligence
Ask anything about Balsalazide disodium
Cited answers from FDA, EMA, Health Canada, PubMed and ClinicalTrials.gov, in seconds. Free, no sign-up.
Evaluating for a team? Book a demo